Live Breaking News & Updates on Nmibc

Stay updated with breaking news from Nmibc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.

United-states , Barcelona , Comunidad-autonoma-de-cataluna , Spain , American , Vilaseca-cabo , Urology-service , American-urological-association-annual-meeting , Urological-association-annual , Bacillus-calmette-gu , Fgfr-altered-non-muscle-invasive-bladder-cancer , On-muscle-invasive-bladder-cancer

Dr Meeks on Harnessing Innovation in Bladder Cancer

Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.

United-states , American , Edwardm-schaeffer , Joshuaj-meeks , American-urological-association-annual-meeting , Molecular-genetics , Northwestern-university-feinberg-school , Urological-association-annual-meeting , Aua-annual-meeting , Joshua-meeks , Nmibc

Urinary MRD Status Potentially Predictive of Recurrence in BCG-Unresponsive NMIBC

Assessment of urinary MRD status identified and enabled quantification of molecular responses with nadofaragene firadenovec in BCG-unresponsive NMIBC.

United-states , Vikramm-narayan , Intravesical-administration , Ferring-pharmaceuticals , Urology-at-emory-university-school-of-medicine , Emory-university-school , Clin-oncol , Medicine-clinical-trials , Patients-with , Relapsed-bladder , Bladder-cancer

Key Takeaways on Evolving Bladder Cancer Treatment Landscape

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

Bladder-cancer , Evolving-bladder-cancer-treatment , Non-muscle-invasive-bladder-cancer , Nmibc , Key-takeaways , Bladder-cancer-treatment , Treating-bladder-cancer , Bladder-cancer-treatment-landscape ,

Approach to Collaborative Care in Bladder Cancer

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

Large-urology-group-practice-association , Bladder-cancer , Collaborative-care , Non-muscle-invasive-bladder-cancer , Nmibc , Bladder-cancer-treatment , Nmibc-treatment , Non-muscle-invasive-bladder-cancer-treatment , Collaborative-care-program , Treating-bladder-cancer , Treating-patients-with-bladder-cancer

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Enfortumab-vedotin , Bladder-cancer , Non-muscle-invasive-bladder-cancer , Nmibc , Ev-104 , Nmibc-treatment , Bladder-cancer-treatment ,

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Bladder-cancer , Non-muscle-invasive-bladder-cancer , Nmibc , Esmo-2023 , Highlights-from-esmo-2023 , Biomarkers , Molecular-biomarkers ,

Bladder Cancer: Treatment Options and Managing Adverse Effects

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Bladder-cancer , Treatment-options , Managing-adverse , Non-muscle-invasive-bladder-cancer , Nmibc , Bcg-treatment , Pembrolizumab , Pd-l1 , Ongoing-trials ,

Cretostimogene Grenadenorepvec Confers High CR Rate in NMIBC

Preliminary findings from the phase 3 BOND-003 trial showed that treatment with cretostimogene grenadenorepvec led to sustained and durable complete responses and a tolerable safety profile in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.

United-states , Washington , Illinois , Philadelphia , Pennsylvania , University-of-pennsylvania , Chicago , American , Arthur-kuan , Trinityj-bivalacqua , Perelman-center , American-urological-association

Nadofaragene Firadenovec Induces Durable Activity in High-Risk, BCG-Unresponsive NMIBC With CIS

Nadofaragene firadenovec-vncg led to encouraging rates of high-grade recurrence-free survival and overall survival in patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Mayo-clinic-in-rochester , Minnesota , United-states , Anne-luther , Stephena-boorjian , Ferring-pharmaceuticals , Carl-rosen-professor , Anne-luther-chair , Mayo-clinic , Bacillus-calmette-guerin , News , Urothelial-cancer